Skip to main content
. 2023 Jun 12;12(14):15207–15216. doi: 10.1002/cam4.6208

FIGURE 2.

FIGURE 2

Progression‐free survival and overall survival. Progression‐free survival from date of enrollment (red dashed line) and overall survival from date of enrollment (blue solid line) for the 10 patients treated with palbociclib and ganitumab. Tick marks indicate patients who were censored.